Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Marco Kesting.
    Summary: "Preface-- Operative treatment for oral cancer is one of the most challenging fields in whole surgery. The perioral region is the only area of the body containing all types of tissue: muscle, bone, cartilage, skin and mucosa. Because of this unique anatomy, ablative tumor surgery and reconstructive surgery remain very complex. On the one hand, the surgeon has to possess elaborate skills in handling the soft tissue, dealing with microvascular techniques and managing bone treatment including osteosynthesis. On the other hand, he has to prepare defined strategies to anticipate any upcoming surgical problem. As there is an overwhelming repertoire of ablative and reconstructive procedures, it is hard for students, residents and young surgeons to find the right way to "survive in the operative jungle." This book concentrates on key procedures that offer young surgeons the possibility to solve almost any case of oral cancer. Basic principles are didactically edited in series of pictures and/or diagrams. Traditional approaches are combined with innovative techniques. Anatomical introductions connect previous knowledge with the surgical procedures. Additionally, historic landmarks and recommendations regarding to the techniques are given in an informational, sometimes anecdotic style. The compact and concise character of the book should enable the resident to study, prepare and recapitulate all issues regarding oral cancer surgery in a short time. Marco Kesting 2014 "--Provided by publisher.
    Digital Access Thieme MedOne Otolaryngology 2015
  • Article
    Rodriguez V, McCredie KB, Keating MJ, Valdivieso M, Bodey GP, Freireich EJ.
    Cancer Treat Rep. 1978 Apr;62(4):493-7.
    Isophosphamide was administered to 27 patients with acute leukemia and to 15 patients with malignant lymphoma refractory to primary therapy. The starting dose of isophosphamide was 1200 mg/m2 administered as a daily continuous infusion x 5 days; the courses of treatment were repeated every 2-3 weeks. Of the 27 patients with acute leukemia, four achieved complete remission, two achieved partial remission, and two achieved hematologic improvement. However, no responses occurred in ten patients with acute myelogenous leukemia (AML). Thus, the response rate was 47% (eight responses among among 17 patients, in patients with acute lymphoblastic leukemia and acute undifferentiated leukemia. Seven of the 15 patients with malignant lymphoma responded. Most responses (five of six patients) occurred in patients with diffuse histiocytic lymphoma. Twenty-one of the 42 patients had received prior therapy with cyclophosphamide and 12 of these patients (two with leukemia and ten with lymphoma) responded, thus suggesting that as in the treatment of L1210 leukemia, isophosphamide is effective for tumors resistant to prior cyclophosphamide therapy. No significant genitourinary toxicity occurred; however, myelosuppression became the dose-limiting toxicity. Isophosphamide is active in malignant lymphomas and acute leukemias (except AML) and may have a role in combination regimens for such diseases.
    Digital Access Access Options